SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-88362"
 

Search: onr:"swepub:oai:DiVA.org:liu-88362" > Predictive role of ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Sörenson, SverreÖstergötlands Läns Landsting,Linköpings universitet,Lungmedicin,Hälsouniversitetet,Lungmedicinska kliniken US,Allergicentrum US (author)

Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • Elsevier,2013
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-88362
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-88362URI
  • https://doi.org/10.1016/j.ejca.2012.07.032DOI
  • https://lup.lub.lu.se/record/3481061URI
  • https://gup.ub.gu.se/publication/173272URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-191988URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:125900221URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Ostergotland County Council, Medical Research Council of South-East Sweden (FORSS)||
  • Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. less thanbrgreater than less thanbrgreater thanMethods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy. Chemotherapy cycle length was three weeks and planned duration of chemotherapy was four cycles. Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity. In a subset of patients, plasma VEGF levels were examined at onset of treatment and at 6, 12 and 20 weeks. less thanbrgreater than less thanbrgreater thanResults: VEGF levels at start of treatment were obtained in 107 patients at four study sites. The median value was 70 pg/ml. Mean values declined during the first 12 weeks and then increased at 20 weeks. A subpopulation treatment effect pattern plot (STEPP) analysis showed an inverse relationship between initial plasma VEGF and the impact of celecoxib on survival with zero effect at 200 pg/ml. The effect on survival by celecoxib in the whole subset of patients was positive (hazard ratio (HR)=0.64 [confidence interval (CI) 0.43-0.95], p=0.028). less thanbrgreater than less thanbrgreater thanConclusion: Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Fohlin, HelenaÖstergötlands Läns Landsting,Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Regionalt cancercentrum(Swepub:liu)helfo18 (author)
  • Lindgren, AndreaÖstergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Allergicentrum US(Swepub:liu)andko90 (author)
  • Lindskog, MagnusKarolinska Institutet,Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap,Cancerfarmakologi och beräkningsmedicin,Uppsala University, Sweden(Swepub:uu)magli409 (author)
  • Bergman, Bengt,1953Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,Sahlgrens University Hospital, Sweden(Swepub:gu)xbeben (author)
  • Sederholm, ChristerÖstergötlands Läns Landsting,Linköpings universitet,Lungmedicin,Hälsouniversitetet,Lungmedicinska kliniken US(Swepub:liu)chrse81 (author)
  • Ek, LarsLund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden(Swepub:lu)lung-lek (author)
  • Lamberg, KristinaUppsala universitet,Lungmedicin och allergologi,University of Uppsala Hospital, Sweden(Swepub:uu)krila642 (author)
  • Clinchy, BirgittaLinköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet(Swepub:liu)bircl77 (author)
  • Linköpings universitetLungmedicin (creator_code:org_t)

Related titles

  • In:European Journal of Cancer: Elsevier49:1, s. 115-1200959-80491879-0852

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view